- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Inhaled Levodopa Product Launches in Germany
The product, sold as Inbrija, is commercialized in Germany through an agreement with Esteve Pharmaceuticals GmbH.
Acorda Therapeutics said recently its levodopa inhalation powder for Parkinson disease (PD) has launched in Germany.
The product, sold as Inbrija, is commercialized in Germany through an agreement with Esteve Pharmaceuticals GmbH.
The inhaled levodopa is indicated in the European Union for the intermittent treatment of episodic motor fluctuations (known as off episodes) in adult patients with PD treated with a levodopa/dopa-decarboxylase inhibitor.
Under the terms of the distribution and supply agreements, Acorda will receive a significant double-digit percent of the selling price of the product in Germany in exchange for supply of the product, and will receive additional sales-based milestones. Acorda expects to start receiving revenue from the supply of the product during the second quarter of 2022.
PD is the second most common neurodegenerative disease in Germany; according to current population estimates, there are up to 400,000 people living with PD in Germany, and there are 20 new cases per 10,000 people per year. Most cases occur between the ages of 55 and 65, and men are diagnosed more often than women.
Acorda had also previously announced an agreement with Esteve to commercialize the inhaled levodopa in Spain with a commercial launch in early 2023 and an agreement with Biopas Laboratories to commercialize the product in Latin America. Acorda said it continues to be in active discussions with additional companies for distribution rights in other countries throughout the world.
“We are excited that INBRIJA is now available to the people with Parkinson’s in Germany who may benefit from a newttreatment to address their OFF periods,” Kerry Clem, chief commercial officer of Acorda Therapeutics, said in a statement. “Esteve has a significant presence in Europe and an excellent track record of successfully commercializing neurological products there.”
Major Study Expands in Hopes to Cure Parkinson Disease
April 19th 2022April is Parkinson’s Disease Awareness month, and on this episode of Managed Care Cast, we take a look at the Parkinson's Progression Markers Initiative (PPMI), a study from the Michael J. Fox Foundation for Parkinson's Research (MJFF). The multicenter, international study aims to end Parkinson disease, which is expected to double worldwide by 2040, to more than 14 million people.
Listen
Certain Patient Groups Continue to Be Underrepresented in PD Studies in the Netherlands
February 4th 2023With greater attention being paid to the heterogenous patient population, researchers questioned whether this has resulted in a more diverse group of patients included in Parkinson disease (PD) studies in the Netherlands.
Read More
An Inside Look at Innovations by MJFF to Assist the Parkinson Community Amid the COVID-19 Pandemic
May 26th 2020On this episode of Managed Care Cast, we speak with Rachel Dolhun, MD, vice president of Medical Communications at The Michael J. Fox Foundation for Parkinson Research, about recent innovations by The Michael J. Fox Foundation to assist patients and families of patients with Parkinson disease in adjusting to this new normal.
Listen
Motor Symptoms May Occur 3 Years Before Parkinson Disease Diagnosis, Study Says
January 20th 2023Trouble with balance and holding objects above one's head were just a few of the problems reported by patients 3 years before they received a formal Parkinson disease diagnosis, according to a recent study.
Read More
